EUCTR2015-004544-18-FR进行中（未招募）1 期
An open-label, randomised, phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated metastatic colorectal cancer who are non-eligible for intensive therapy
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent obtained.
- •- Male or Female participant aged =18 years old.
- •- Has ECOG performance status of 0, 1 or 2 at the time of the randomisation.
- •- Has definitive histologically or cytologically confirmed adenocarcinoma of the colon or rectum.
- •- RAS status must have been determined (mutant or wild).
- •- Has at least one measurable metastatic lesion.
- •- No previous anticancer therapy for metastatic colorectal cancer.
- •- Previous adjuvant (or neoadjuvant for patients with rectal cancer) chemotherapy is allowed only if if it has been completed more than 6 months before start of study treatment.
- •- In the judgment of the Investigator, patient is not a candidate for combination chemotherapy with irinotecan or oxaliplatin, or for curative resection of metastatic lesions.
- •- Is able to take medication orally (i.e., no feeding tube).
- •- Has adequate organ function.
- •- Coagulation parameters in normal limit.
- •- Women of childbearing potential must have been tested negative in a serum pregnancy test. Male and female patients who have the potential to reproduce must agree to use a highly effective method of birth control.
- •- Is willing and able to comply with scheduled visits and study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 110
排除标准
- •- Foreseeable poor compliance to the study procedures.
- •- Is a pregnant or lactating female.
- •- Is inappropriate for entry into this study in the judgment of the Investigator.
- •- Has certain serious illness or serious medical condition(s) described in the protocol.
- •- Has had certain other recent treatment e.g. major surgery, field radiation, received investigational agent, within the specified time frames prior to study drug administration.
- •- Has previously received S 95005 or history of allergic reactions attributed to compounds of similar or biologic composition to S 95005.
研究者
相似试验
进行中（未招募）
1 期
A phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 18.1Level: PTClassification code 10052358Term: Colorectal cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-ESaboratorios Servier S.L.154
进行中（未招募）
1 期
A phase 2 study comparing S 95005 plus bevacizumab to capecitabine plus bevacizumab in patients with previously untreated colorectal cancer who are non-eligible for intensive therapyMetastatic colorectal cancerMedDRA version: 20.0 Level: PT Classification code 10052358 Term: Colorectal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004544-18-DEInstitut de Recherches Internationales Servier150
进行中（未招募）
1 期
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomyMedDRA version: 20.0Level: LLTClassification code: 10007113Term: Cancer of prostate Class: 10029104Prostate cancerCTIS2024-512023-37-00GasthuisZusters Antwerpen202
招募中
2 期
A phase II, randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomyProstate cancer2024-512023-37-00Ziekenhuis Aan De Stroom202
招募中
1 期
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K inhibitor inavolisib in patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer - GeparPiPPaMedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864Breast CancerCTIS2022-501152-28-00GBG Forschungs GmbH220